Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Aquaftem is a perfluorocarbon-based emulsion designed to enhance oxygen delivery to tissues. Originally derived from the "Perftoran" blood substitute technology developed in the Soviet Union, Aquaftem is primarily utilized in topical and cosmetic applications to improve skin oxygenation, accelerate wound healing, and enhance the penetration of other active ingredients. The mechanism of action relies on the high gas-solubility of perfluorocarbons, such as perfluorodecalin and perfluoromethylcyclohexylpiperidine, which act as physical carriers for oxygen and carbon dioxide. These compounds facilitate gas exchange at the cellular level by dissolving atmospheric oxygen and releasing it into the hypoxic environment of the skin or wound bed. It is most notably associated with the Russian company Faberlic, which integrated the technology into its "oxygen cosmetics" line for anti-aging and restorative purposes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Aquaftem.